

*Law Offices of*  
***KIMBERLY L. GRAUS, P.A.***

4949 State Road 64 East, PMB #141  
Bradenton, Florida 34208  
(941) 747-5290 phone  
(866) 640-6858 facsimile  
[kgraus@tampabay.rr.com](mailto:kgraus@tampabay.rr.com)

September 13, 2011

OTC Markets Group, Inc.  
304 Hudson Street, 2nd Floor  
New York, NY 10013

**Re: Legal Opinion, Adequate Current Information, Continuing Disclosure Requirements, SOLOS ENDOSCOPY, INC., Quarter ending June 30, 2011.**

This office has been engaged by **SOLOS ENDOSCOPY, INC.**, a Nevada corporation (the "Issuer") as its securities counsel and particularly for purposes of this opinion.

This opinion may be posted on the Pink Sheets news service for viewing by the general public and Pink Sheets may rely on said opinion in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c) (2) of the Securities Act of 1933. Additionally, the Issuer's posted information includes all the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 and complies as to form with the Pink Sheets Guidelines for Providing Adequate Current Information.

Counsel is licensed in and resides in the State of Florida. Counsel is permitted to practice before the Securities and Exchange Commission and has not been prohibited from practice thereunder.

For purposes of this opinion counsel has reviewed the:

1. Issuer's Quarterly Disclosure Statement for the period ending June 30, 2011 and posted August 19, 2011;
2. Issuer's Quarterly Financial Statement for the period ending June 30, 2011 and posted August 19, 2011;
3. All prior disclosures posted by the Issuer with OTC Disclosure and News Service; and
4. Such other corporate records as were necessary and provided by management for purposes of this letter.

The opinion and conclusions herein are based upon documentation and facts made available by the Issuer and is based on the accuracy of those documents and facts. Additionally counsel has reviewed all prior disclosures posted by the Issuer with OTC Disclosure and News Service other than those listed above. All such information is believed to be true. In the event that the facts and information in all such documents are determined not to be true, this opinion shall be null and void.

Counsel has personally met and discussed with a majority of the Board of Directors and management of the Issuer the Information provided and has received representations from the Issuer, its management and directors as to the accuracy of the information provided for review. This opinion is further based upon those representations.

The corporate offices of the Issuer are located at 65 Sprague St., West B, Boston, MA 02136. The primary business of the company is the provision of specialty medical supplies to doctors and hospitals.

As of June 30, 2011, the authorized capital of the Issuer was 500,000,000 shares of Common stock, Par Value \$.001; and 10,000,000 Preferred shares, Par Value \$.001, 9,900,000 of which are designated as Series A and 100,000 of which are designated as Series B. As of June 30, 2011, based on the Transfer Agents' Complete Stockholders List of even date, there were 76,957,710 shares of Common stock issued and outstanding. Pursuant to the Company's representations of even date, as of June 30, 2010, there were zero shares of Series A Preferred Stock outstanding and 4,000 shares of Series B Preferred Stock outstanding.

The Fiscal year end for the Issuer is December 31. Financial Statements of the Issuer are prepared by Fred V. Schiemann, CPA and are not audited. These statements are then reviewed by management prior to filing. The primary officer reviewing and approving the Company's financial statements is Mr. Robert Segersten. Mr. Segersten is the President and CEO of the Company. Mr. Segersten has Bachelors degree from Bates College and a Juris Doctorate from Boston University. He has been in this industry since 1991 and has been President of the Company since 2000.

There are no known threatened legal proceeding against the Issuer and there are no known defaults on senior securities other than those disclosed in the posted Issuers Disclosure Statement.

The Transfer Agent for the Issuer is Pacific Stock Transfer, 500 E. Warm Springs Road, Suite 240 Las Vegas, NV 89119: Phone: (702) 361-3033; Fax (702) 433-1979. The agency is registered with the SEC.

In rendering the conclusion expressed below, I advise you that I am a member of the Florida Bar and express no opinion herein concerning the applicability or effect of any laws of any other jurisdiction, except the securities laws of the United States of America referred to herein.

This opinion letter has been prepared and is to be construed in accordance with the Report on Standards for Florida Opinions dated April 8, 2001, as amended and supplemented, issued by the Business Law Section of The Florida Bar (the "Report"). The Report is incorporated by reference into this opinion letter.

Further to a review of the books and records of the Issuer and discussions with management, counsel is of the opinion that (i) the information provided by the Issuer and posted on the Pink Sheets web site constitutes "adequate public information" concerning the Securities of the Issuer and is "available" within the meaning of Rule 144(c) (2) of the Securities Act of 1933; and (ii) to the best of counsel's knowledge, neither the Issuer nor any 5% holder of stock of the company is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws, except with respect to Big Apple Consulting, USA, Inc. ("Big Apple"). Big Apple held approximately 5.2% of the Company's outstanding common stock as of June 30, 2011. The SEC filed a complaint against Big Apple on November 18, 2009 (Case Number 09-cv-1963 (M.D. Fla.) alleging violations of the Securities Act and the Exchange Act in connection with certain press releases and other promotional activities of CyberKey Solutions, Inc., a former Big Apple Client.

This opinion may be posted on the OTC Disclosure and News Service for viewing by the general public and OTC Markets Group may rely on said opinion in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c) (2) of the Securities Act of 1933. This opinion letter is not to be relied on by any other party or for any other purposes.

Additionally, the information posted by the Issuer includes all the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 and complies as to form with the Pink Sheets Guidelines for Providing Adequate Current Information.

Counsel looks forward to making further disclosures to OTC Disclosure and News Service as required or as requested by OTC Markets Group or the Issuer. If you have any questions, please call me at 941.747.5290.

Sincerely,  
Kimberly L. Graus, P.A.

A handwritten signature in black ink, appearing to read "Kimberly L. Graus", written in a cursive style.

Kimberly L. Graus